Tech Company Inital Public Offerings
Fusion Pharmaceuticals IPO
Fusion Pharmaceuticals was bought by . Fusion Pharmaceuticals shares started trading on 6/26/2020.
Transaction Overview
Company Name
Announced On
6/26/2020
Transaction Type
IPO
Amount
$213,000,000
Proceeds Purpose
Use of proceeds for the Fusion Pharmaceuticals IPO are outlined in the company's S1 filing.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
451 D St. 930
Boston, MA 02110
USA
Boston, MA 02110
USA
Phone
Website
Email Address
Overview
Fusion Pharmaceuticals is a spinout of the Centre for Probe Development and Commercialization (CPDC), a leading radiopharmaceutical research and GMP production centre.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Valliant
Chief Financial Officer
John Crowley
Chief Scientific Officer
Eric Burak
VP - Bus. Development
Marc Schwabish
VP - Finance
Lynn Wick
Browse more venture capital transactions:
Prev: 6/25/2020: Derivative Path venture capital transaction
Next: 6/26/2020: Doorkee venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs